Researchers analyzed data from 20 people with MYT1L variants in the Brain Gene Registry, combining genetic information, remote behavioral assessments and electronic health records. Fourteen participants had pathogenic or likely pathogenic variants; the rest had variants whose effects were uncertain.

Those with confirmed MYT1L-related disorder showed marked difficulties in nonverbal cognition and adaptive functioning, especially motor tasks, communication and daily living. Behavioral assessments found frequent ADHD symptoms, conduct problems, oppositional behavior and anxiety, while records also showed recurring developmental delays, speech and language disorders, gastrointestinal problems and obesity. Prescriptions commonly included alpha-2 adrenergic agonists and laxatives.